Abstract Details

Title Blood IgM Anti-GAGA4 in the Diagnosis of Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 240

Objective

Background BACKGROUND: Blood IgM anti -Glc(?-1,4)Glc(?) (anti -GAGA4) levels studied by a new test (gMSDx) seem to differentiate clinically isolated syndrome (CIS) / or relapsing remitting multiple sclerosis (RRMS) from other neurological diseases (OND).

Design/Methods DESIGN/METHODS: 281 neurological patients were recruited and followed for at least 12 months. Clinical data and sera were collected at the beginning of the study. MS Diagnosis was defined by McDonald 2010 criteria. Frozen sera were analyzed for gMSDx (Glycominds, US). Patients were characterized using a previously defined cutoffs, as positive if >55, or high positive if >80 EU/(Total IgM mg/mL)0.5.

Results RESULTS: 136 patients (69% females) were diagnosed as MS, 9 remained as CIS or radiological isolated syndrome, 136 (55% females) were diagnosed as other neurological disease (OND). MS patients had significantly higher levels of IgM anti-GAGA4 normalized to total IgM than OND patients (p=0.004). 47/136 MS patients were positive vs. 26/136 OND (p= 0.009). Sensitivity, specificity, positive and negative likelihood ratios at cutoff>55EU/(Total IgM mg/mL)0.5 were: 35%, 81%, 1.8 and 0.8; at cutoff>80EU/(Total IgM mg/mL)0.5 were: 12.5%, 94%, 2.1 and 0.9. In the OND group, only 7/136 were high positive (95% specificity).

Conclusions CONCLUSIONS: This first prospective analysis of a "real life" consecutive cohort validates that gMSDx blood test discerns a subgroup of CIS/RRMS from OND.

Authors/Disclosures
Luisa Maria Villar Guimerans, MD (Hospital Universitario Ramon Y Cajal) PRESENTER	No disclosure on file
	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
	No disclosure on file
Nir Dotan	No disclosure on file
Avinoam Dukler, PhD (Kepler Diagnostics, Inc)	No disclosure on file
Jose Carlos Alvarez Cermeno, MD (Hospital De Colmenar Viejo)	No disclosure on file

��ɫ��

��ɫ��